Hormonal
Tournament wrestling involving 6% body weight loss followed by multiple matches over two days causes progressive, significant reductions in lower body power and upper body isometric strength, alongside elevated physiological stress markers (testosterone, cortisol, lactate, norepinephrine, epinephrine, and plasma osmolality).
If you are a wrestler, be aware that losing 6% of your body weight and then competing in multiple matches over two days will significantly reduce your strength and power. Your body will also experience high levels of stress, indicated by changes in hormones and metabolic markers. To maintain performance, consider strategies that minimize extreme weight loss and prioritize recovery between matches.
Lower body power and upper body isometric strength were significantly reduced as the tournament progressed (P < 0.05). Significant elevations in testosterone, cortisol, and lactate were observed after each match (P < 0.05). However, there was a significant reduction (P < 0.05) in resting testosterone values in the later matches. Norepinephrine increased significantly (P < 0.05) after each match, whereas epinephrine increased significantly (P < 0.05) after each match except the last match of each day. Plasma osmolality was consistently higher than normal values at all times including baseline, with significant increases observed after each match (P < 0.05).
Why this rating
Randomized controlled trial design with a specific, well-defined population (Division I collegiate wrestlers) and rigorous testing battery, though limited to a single sample of 12 subjects.
Source
Physiological and performance responses to tournament wrestling
William J. Kraemer et al. · Medicine & Science in Sports & Exercise · 2001
DOI 10.1097/00005768-200108000-00019
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →